Diagnostic studies Sample Clauses

Diagnostic studies. Reports on interviews with Xxxxxx Youth/NMD;
Diagnostic studies. PLEASE LIST THE APPROXIMATE DATE OF TEST, THE NAME OF THE FACILITY WHERE THE TEST WAS PERFORMED, THE NAME OF THE ORDERING PHYSICIAN AND THE RESULTS, IF KNOWN. TEST DATE FACILITY PHYSICIAN RESULTS EMG 0000 Xxxxxxxxx Xxxx XX Xxxxxxx, XX 00000 Patient Name : Account #: MR # : Date : Headaches Trouble with hearing Trouble with eyesight Nasal discharge Hay Fever, frequent sneezing Sinus trouble, post nasal drip Hoarseness Ulcer of tongue or mouth Trouble with gums or teeth Sore throat Asthma, wheezing Cough Cough up blood Tuberculosis Shortness of breath High blood pressure Chest pain Irregular beat or palpitation of heart Increased thirst, hunger Sudden weight change Sensitive to heat/cold Change in skin, body hair Change in sex drive Rash Tumor on skin Frequency urgency or pain with urination Passed blood or kidney stone Trouble starting or stopping of urinary stream Trouble swallowing Abdominal pain, nausea, vomiting Acid Reflux (“Heartburn”) Stomach ulcer/Duodenal ulcer Black bowel movements Diarrhea Constipation Hemorrhoids or rectal itching Low back pain Joint pain Arthritis Neck pain Backache Balance prolems Numbness or tingling anywhere Weakness Trouble walking Problems with sleep Dizziness Depression Fatigue Anemia or difficulty with bleeding Sexual problems Awaken at night with shortness of breath Please check any of the following below that you have had or currently have a problem with: Alcohol Acquired Brain Injury ALS Asthma Bladder Pain / Spasms Blood Clots Blood in Stool Blood in Urine Cerebral Palsy Cigarettes Current Pregnancy Diabetes Drugs Dysreflexia Frequent UTI Gynecological Problems Hay Fever / Allergies High Blood Pressure HIV (or AIDS) Impaction Kidney Failure Multiple Sclerosis Neurogenic Bladder Neurogenic Bowel Paraplegia Pneumonia Post Polio Psychiatric Problems Respiratory Failure Quadriplegia / Tetraplegia Seizures Skin Problem Xxxxx Bifida Spinal Problems Stroke Ventilator Use 0000 Xxxxxxxxx Xxxx XX Xxxxxxx, XX 00000 Date Patient Name Medical Record Number
Diagnostic studies. Report of interviews with YOUNfi ADULT.
Diagnostic studies. 1. Carrying out of a comprehensive diagnostic study aimed at assessing all the current arrangements covering the financial, operational, technical, legal and contractual aspects pertaining to the exploitation of oil resources and the management of oil revenues with a view to designing a comprehensive reform program aimed at improving the management of the Borrower’s petroleum sector. 2. Carrying out of a procurement assessment review with a view to improving the legal and regulatory framework for procurement operations. Part E: Economic Policy Formulation and Capacity Building 1. Strengthening the Borrower’s capacity to formulate appropriate economic policies and to coordinate and monitor their implementation specifically in the areas of: (a) civil service reform; (b) fiscal federalism; and (c) trade policy reform; all through the provision of technical advisory services and the carrying out of seminars/workshops, and study tours. 2. Carrying out a training program for relevant staff of the Borrower involved in the carrying out of any part of the Project in subject matters related to the implementation of the said parts of the Project. (a) Establishment of a distance learning center, to increase the access of the Borrower’s and private sector managers to global innovations and information. (b) Installation in DLC of (i) a video-conference room with about a fifty
Diagnostic studies. Reports on interviews with Youth/NMD; 3 4 5 professionals; medical/dental visits and
Diagnostic studies. Reports on interviews with xxxxxx child;

Related to Diagnostic studies

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • Trials The Ship shall run the following test and trials: (1) Harbour Acceptance Tests, including setting to work of the various equipment;

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Diagnostic Assessment 6.3.1 Boards shall provide a list of pre-approved assessment tools consistent with their Board improvement plan for student achievement and which is compliant with Ministry of Education PPM (PPM 155: Diagnostic Assessment in Support of Student Learning, date of issue January 7, 2013). 6.3.2 Teachers shall use their professional judgment to determine which assessment and/or evaluation tool(s) from the Board list of preapproved assessment tools is applicable, for which student(s), as well as the frequency and timing of the tool. In order to inform their instruction, teachers must utilize diagnostic assessment during the school year.

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.